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ABSTRACT
There is increasing evidence and appreciation of
idiopathic intracranial hypertension (IIH) in
medicine. The pathological processes underly-
ing raised intracranial pressure are being stud-
ied, with new insights found in both hormonal
dysregulation and the metabolic neuroen-
docrine axis. These will potentially lead to novel
therapeutic targets for IIH. The first consensus
guidelines have been published on the investi-
gation and management of adult IIH, and the
International Headache Society criteria for
headache attributable to IIH have been modi-
fied to reflect our evolving understanding of
IIH. Randomized clinical trials have been pub-
lished, and a number of studies in this disease
area are ongoing.
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Why carry out this study?
Investigation and management strategies
have been recommended by the first
consensus guidance for IIH.
Understanding the underlying
pathophysiology of IIH is identifying
novel avenues for targeted therapies.
What was learned from the study?
This review summarizes the IIH
pathophysiology known to date.
It presents an evaluation of the
randomized controlled trials in IIH.
It details the potential targets for future
disease management.
DIGITAL FEATURES
This article is published with digital features to
facilitate understanding of the article. To view
digital features for this article go to https://doi.
org/10.6084/m9.figshare.12547667.
INTRODUCTION
Idiopathic intracranial hypertension (IIH), also
known as primary pseudotumour cerebri syn-
drome, is a neurological disorder characterised
by raised intracranial pressure (ICP) that can
cause papilloedema with no identifiable cause
found [1, 2]. There is a rising incidence of this
disease, which is most common in females of
working age [3, 4], and appears to be related to
the prevalence of obesity [4, 5], the major
known risk factor for the disease [1, 6]. IIH is
associated with headache, which impacts qual-
ity of life [7]; over half of those with IIH report
ongoing headaches at 12 months following
initial diagnosis [8]. IIH can cause visual loss,
even to the level of severe visual impairment or
legal blindness [9]. Current medical treatments
are often poorly tolerated [10], and the overar-
ching research aspirations of both patients and
clinicians are to understand the aetiology and
management of IIH, with particular focus on
headache [11]. The recent guidance in IIH
acknowledges uncertainties in many aspects of
the disease [1]. Novel targets are now being
identified, and insights into monitoring disease
activity are improving [12]. This article is based
on previously conducted studies and does not
contain any studies with human participants or
animals performed by any of the authors.
EPIDEMIOLOGY OF IIH
IIH is considered a rare disease; however,
increasing numbers of patients are being
reported. Previously, the incidence in the gen-
eral population was reported to be between 0.5
and 1.0 per 100,000 [5]. Comparing rates within
the United Kingdom (UK) between the years
2007 and 2008, Raoof et al. found the incidence
of IIH was 1.56 per 100,000 for men and 2.86
per 100,000 for women [12, 13]. Recent evi-
dence indicates a greater than 100% increase in
the incidence of IIH in England between 2002
and 2016, which rose from 2.3 to 4.7 per
100,000 in the general population [3]. In
females, the incidence of IIH more than tripled
between 2005 and 2017, from 2.5 to 9.3 per
100,000 person-years, and increased markedly
in those with a body mass index (BMI) higher
than 30 kg/m2 [4]. Adult women are more likely
to develop IIH than men, with a peak incidence
in females aged 25 years of 15.2 per 100,000 [3].
Worldwide, IIH is more common in countries
such as the UK [3, 13], Italy [14], Israel [15] and
the USA [16], while incidence is lower in Asia
[17, 18]. A recent systematic review identified a
positive correlation between a country-specific
prevalence of obesity and incidence of IIH [6].
The incidence of IIH in childhood is esti-
mated to be around 0.5 per 100,000 [19, 20].
Paediatric IIH has been classified by anthropo-
metric features, with three identifiable sub-
groups of paediatric IIH: a young cohort that is
not overweight, an early adolescent group that
is either overweight or obese, and a late
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adolescent group that is mostly obese. This
indicates that the underlying pathological
mechanisms for IIH may differ depending on
age and BMI [21].
PATHOPHYSIOLOGY
The pathological processes underlying elevated
ICP in IIH patients are unknown. Current
research is focused on understanding the
respective roles of obesity, increased cere-
brospinal fluid (CSF) production and hormonal
dysregulation. Additional theoretical mecha-
nisms, such as venous hypertension and
reduced CSF absorption, may also play a role in
the pathophysiology of IIH [2, 22, 23]. There is
however an emerging theme that IIH is a neu-
rometabolic disease [23]. Adderley et al. found a
twofold increase in cardiovascular disease risk in
women with IIH compared to age-, sex- and,
most importantly, BMI-matched controls [4].
This suggests that multiple factors may be
driving the disease.
Obesity
There is a well-established link between IIH and
obesity [6, 24]; the prevalence of IIH in popu-
lations with a higher BMI is greater than in the
general population [5]. The dramatic rise in
obesity rates globally [25] is mirrored in the
rising incidence of IIH [3, 5, 26]. Daniels et al.
found that, compared to controls, patients with
IIH reported higher weight gain in the 1-year
period prior to the onset of the disease. Higher
BMI and weight gain percentage were also
associated with higher (dose-dependent) risk of
IIH. Interestingly, weight gain of just 5–15% can
lead to an increased risk of IIH [27]. Ko et al.
found that patients who experienced a recur-
rence of IIH following symptom resolution
showed weight gain of just 6% of total body
weight [24]. Records were analysed over a
16-year period at two hospitals, and the authors
found that 26 out of the 50 patients analysed
had IIH recurrence (increase in an average BMI
of 1.3 per year), and the 24 who had no recur-
rence did not gain weight (average decrease in
BMI of 0.96 per year) [24]. This shows the
exquisite sensitivity between even modest
weight gain and recurrence of IIH. Adderley
et al. reported that the incidence of IIH
increased rapidly above a BMI of 30 kg/m2 [4].
This evidence reinforces the close link between
obesity and IIH.
Lifestyle interventions such as diet and
exercise have long been known to be an effec-
tive treatment for IIH; the first study to
demonstrate the effectiveness of a lifestyle
intervention for improvement of IIH symptoms
was carried out in 1974 [28]. In the mid-1990s,
the first cases of bariatric surgery for IIH were
reported [29]. Previous literature shows that
between 3 and 15% loss in body weight is
required to put the disease into remission. An
objective evaluation of weight loss in IIH was
performed as a prospective crossover cohort
trial using a very low-calorie meal replacement
to induce significant weight loss, defined as a
loss of 15% or greater of total body weight. Such
weight loss resulted in significantly lowered ICP
and improved papilloedema, visual function
(perimetry and acuity) and headache outcomes
(50% improvement in headache frequency,
severity and frequency of analgesic use) [30]. In
the Idiopathic Intracranial Hypertension Treat-
ment Trial (IIHTT), a randomised controlled
trial (RCT) investigating the use of acetazo-
lamide in IIH patients with mild visual loss, the
treatment group used acetazolamide, and both
groups (placebo and treatment) were provided a
low-sodium diet with behavioural weight man-
agement support. The treatment group experi-
enced an average 6% weight loss compared to
3% weight loss in the controls [31]. The IIHTT
used a psychological statistical method to report
that weight loss did not mediate the treatment
effect of acetazolamide.
Distribution of body fat in IIH has been
investigated, and it was demonstrated that
truncal fat mass was the only parameter that
correlated with lumbar puncture pressure, as
compared with limb fat mass, BMI, waist cir-
cumference and total fat mass [32]. A relation-
ship has been established between truncal
weight loss in patients with IIH and a reduction
in disease activity [30].
The relationship between obesity and IIH in
men is less clear, although men appear to be at
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risk of greater vision loss and obstructive sleep
apnoea if they have IIH [33].
CSF Dysregulation
CSF is secreted by the choroid plexus, which
consists of epithelial cells lining the ventricles
in the brain. CSF secretion is driven by the net
movement of sodium ions (Na?) from the blood
to the cerebral ventricles, creating an osmotic
gradient down which water moves. Although
several channels are involved in this process,
the principle channel and rate-limiting step is
the Na?- and K?-dependent adenosine triphos-
phatase (Na?/K?/ATPase) that actively trans-
ports Na? into the cerebral ventricle [34, 35].
CSF flows through the ventricles and into the
subarachnoid space, before being returned to
the bloodstream via arachnoid granulations.
Specific inhibition of Na?/K?/ATPase with
ouabain has been shown to reduce CSF secre-
tion by 70–80% [36].
Aquaporins (AQPs), membrane-bound water
transport channels, are thought to be involved
in the osmotic homeostasis of the brain.
Research has not demonstrated a pathogenic
role for AQP4 in the genesis of IIH [37]. AQP1,
another channel, appears to be important in
drug-induced elevation of ICP, and animal
studies show a link between obesity, AQP1
expression and raised ICP [38]. However, no
investigations of the role of AQP1 in IIH in
humans have yet been reported.
Impaired drainage of CSF into the subarach-
noid space is another potential source of IIH.
The turnover of CSF was found to be reduced in
patients with papilloedema [39]. Patients with
IIH have been shown to have abnormalities in
blood clotting [40], and it has been suggested
that microthrombi could cause impaired CSF
drainage in IIH [41]. However, no direct evi-
dence of microthrombi causing raised ICP has
been shown to date.
Glucagon-Like Peptide 1
Glucagon-like peptide-1 (GLP-1) is an incretin
with weight-modifying properties, and has been
shown to have a natriuretic effect in the kidney
through inhibition of the Na?/H? exchanger in
proximal tubule cells. CSF secretion, as dis-
cussed above, is controlled by Na?/K?/ATPase
channels and pumps fluid into the ventricles
akin to an inverted renal proximal tubule.
Exploratory work showed that the choroid
plexus expresses GLP-1 receptor [42]. Botfield
et al. thus hypothesised that GLP-1 could
modulate CSF secretion at the choroid plexus,
thereby mediating ICP [42]. Following from
this, it was demonstrated that exendin-4, a GLP-
1 receptor agonist, significantly reduced the
activity of Na?/K?/ATPase. In a rodent study,
Botfield et al. showed that exendin-4 led to a
65% reduction in ICP within 30 min of admin-
istration, and that its effect on ICP was cumu-
lative. This finding is now being translated into
the IIH Pressure Clinical Study (IIHPCS;
ISRCTN12678718). The IIH pressure study is a
double-blinded, placebo-controlled physiology
study assessing the effects of exenatide on ICP
in patients with active IIH, and is expected to
report soon.
Glucocorticoid Metabolism
Glucocorticoid metabolism has previously been
characterised in IIH subjects before and after
therapeutic weight reduction. 11b-Hydroxys-
teroid dehydrogenase type 1 (11b-HSD1) is an
intracellular enzyme that converts inactive
cortisone into the active cortisol. This amplifies
local glucocorticoid activity independent of
systemic cortisol [43]. Global 11b-HSD1 activity
was found to decrease with weight loss, and a
significant correlation was found between the
reduction in ICP and the decrease in global 11b-
HSD1 activity [44]. It is now known that 11b-
HSD1 is expressed and has activity in the
choroid plexus epithelial cells, along with other
key elements of the glucocorticoid signalling
pathway. Inhibitors of 11b-HSD1, such as oral
AZD4017, have been developed for type 2 dia-
betes mellitus, obesity and metabolic syndrome.
The IIH Drug Trial hypothesised that specific
inhibition of 11b-HSD1 using such drugs may
decrease ICP in individuals with IIH, which
could open an entirely novel therapeutic
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avenue for targeting the disease [45]. The results
of this trial are presented later in this article.
Hormonal Dysregulation
Hormonal dysregulation has been shown to
play an important role in the pathogenesis of
IIH [2, 22, 23]. Androgens have been identified
as potential key players in IIH pathophysiology.
Serum testosterone, and the enzyme 5a-reduc-
tase involved in its metabolism, has been shown
to be higher in those with IIH compared to age-
and BMI-matched controls [46]. In a recent
study that comprehensively compared the sys-
temic and CSF androgen metabolome in
women with IIH to sex-, BMI- and age-matched
control groups with either simple obesity or
polycystic ovary syndrome (PCOS), IIH women
showed a pattern of androgen excess with
increased serum testosterone and increased CSF
testosterone and androstenedione [47]. This was
found to be distinct from that observed in PCOS
and simple obesity. The authors went on to
show that human choroid plexus expressed the
androgen receptor, alongside the androgen-ac-
tivating enzyme aldo-keto reductase type 1C3,
and in a rodent model testosterone significantly
enhanced the activity of Na?/K? ATPase, a sur-
rogate of CSF secretion. In summary, androgens
can modulate CSF secretion via the choroid
plexus, and these findings implicate androgen
excess as a potential causal driver for IIH and
therefore a potential therapeutic target [47].
The hormone leptin plays an important role
in the regulation of fat storage. Leptin is secre-
ted by adipocytes, and its concentration in the
body correlates with total body fat [48]. Higher
serum leptin has been demonstrated in IIH
patients, controlling for age and BMI, indicat-
ing that leptin dysregulation may be important
in IIH [49]. Another study showed that leptin
was elevated in the CSF of IIH patients, though
there was no correlation with leptin CSF levels
and BMI [50]. However, leptin is secreted dis-
proportionately from subcutaneous fat com-
pared to visceral fat [51], and since neither of
these studies accounted for fat distribution,
elevation of leptin in IIH patients may be a
secondary effect of non-central body adiposity.
These studies indicate that the role of leptin in
IIH warrants further investigation.
Venous Hypertension
Increased dural venous sinus pressure has been
proposed as a potential mechanism underlying
IIH. Neuroimaging studies have established that
venous sinus stenosis is a common finding
among patients with IIH [52, 53], yet the extent
of stenosis and the clinical course of IIH are still
to be fully correlated [52]. Reducing the ICP by
removal or diversion of CSF has been shown to
reduce dural venous stenosis [54], and these
findings may indicate that the stenosis may be a
consequence, rather than a cause, of IIH [55].
Despite good evidence of the effect of stenting
on the venous sinus pressure gradient, the effect
on CSF pressure is less clearly understood. There
are many uncontrolled institutional case-based
series reporting resolution of papilloedema and
improvement in headache following venous
sinus stenting, which is discussed below in
management of IIH.
CLINICAL PRESENTATION
Headache is present in over 90% of people
diagnosed with IIH. The phenotype of increased
ICP headache is no longer thought of as an early
morning headache [56], and migraine is now
reported to be the predominant phenotype [57].
The International Headache Society criteria
have been modified to reflect that improvement
in headache with ICP reduction is no longer a
requirement as a diagnostic criterion of head-
ache attributable to IIH [58]. Pulsatile tinnitus,
either unilateral or bilateral, is commonly
reported in IIH. Transient visual obscurations
are common in IIH and are described by
patients as ‘greying’ or ‘blacking out’ of vision
in one or both eyes and lasting seconds. Tran-
sient visual obscurations are usually associated
with changes in posture. Unilateral or bilateral
sixth-nerve palsy may occur secondary to raised
ICP and cause horizontal diplopia [22]. Cogni-
tive function has been reported to be affected in
IIH [59].
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To confirm a diagnosis of IIH, papilloedema
needs to be present, and care must be taken in
the examination of the optic nerve, as papil-
loedema can be misdiagnosed. This has led to
unnecessary investigations, procedures and
therapy, with the leading reason being the
incorrect interpretation of the optic nerve
appearance during clinical examination [60].
Examination of the eye can be challenging, and
where diagnostic uncertainty exists, the guide-
lines recommend that papilloedema be con-
firmed by an experienced specialist [1, 61].
The detection of papilloedema by fundus
photography is extremely sensitive, even
among non-specialists such as emergency
medicine doctors. However, it is of note that
none of the cases presented in a recent study by
Blanch et al. had subtle papilloedema (Frisén
grade 1), which can present the diagnostic
dilemma of papilloedema versus pseudopapil-
loedema [62]. Other imaging tools such as
optical coherence tomography (OCT) and fun-
dus fluorescence angiography (FFA) are helpful
[1, 61]. More evidence of the utility of OCT and
OCT angiography in defining papilloedema
from pseudopapilloedema is emerging [63, 64].
These findings need to be validated across the
different OCT device platforms and larger data
sets to enable clinicians to implement their
findings in routine clinical care.
INVESTIGATION OF PAPILLOEDEMA
In 2018, the first consensus IIH guidance was
published [1]. The IIH guidelines highlighted
the importance of accurate clinical phenotyp-
ing, particularly when diagnosing papilloedema
[1, 65]. On confirmation of true papilloedema,
comprehensive parameters of visual function,
including visual acuity, colour vision, pupil
assessment, dilated fundus examination and
formal visual fields, should be noted, as this will
determine the management course. Blood
pressure must be measured to exclude malig-
nant hypertension. Neuroimaging should then
be performed to exclude secondary causes of
elevated ICP and to identify structural alter-
ations associated with raised ICP. Typical neu-
roimaging features of raised ICP include a
partial empty sella turcica, flattening of the
posterior optic globe, enlargement of the optic
nerve sheath and increased tortuosity of the
optic nerve. CT or MR venography should be
performed to exclude a venous sinus thrombo-
sis, which may mimic IIH in up to a third of
cases [66]. As there is different treatment for
venous sinus thrombosis, and delay in the
diagnosis potentially causes significant mor-
bidity, it is recommended that venography be
performed at the same time as initial neuro-
imaging [1, 61].
Lumbar puncture (LP) is mandatory and
forms part of the diagnostic criteria for IIH [67]
in addition to normal CSF composition analy-
sis. Diagnostic criteria require that opening
pressure be measured in the lateral decubitus
position with stretched legs, and without seda-
tive medications. There is increasing consensus
that there is no single absolute cut-off which is
abnormal, but there is indication of a ’grey
zone’ at which the LP opening pressure may
become increasingly pathological (between 25
and 30 cm CSF) [1, 61].
Blood tests may be performed to investigate
for secondary causes of raised ICP. Other med-
ical conditions such as anaemia, endocrine
causes and vitamin A excess may present with
symptoms similar to IIH [68, 69]. In those
patients who do not fit the typical phenotype
for IIH (i.e. female, of childbearing age and who
have a BMI greater than 30 kg/m2), a thorough
drug history and exclusion of endocrine causes
is required to exclude an underlying cause
[1, 61].
MANAGEMENT OF IIH
The guidelines set out three key principles for
the management of IIH: first, addressing the
underlying modifiable risk factor of weight
gain; second, protecting the vision through
regular assessment and escalation of treatment
when sight is threatened; and finally, reducing
headache morbidity through active manage-
ment [1]. The specialist interest group involved
in establishing these guidelines recognised that
a small proportion of people with IIH are at risk
of rapid permanent visual loss [9] and require
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urgent surgical management, termed fulminant
IIH (Table 1) [1]. The guideline touched on finer
areas of practice including co-morbid condi-
tions, pregnancy, managing headache in the
shunted patient and IIH without papilloedema.
It also gave consensus recommendations for the
timely follow-up of patients reflecting the status
of their optic nerve head and visual field
assessment [1]. The major achievement of this
document is the interdisciplinary effort to pro-
vide a framework for equal care for those with
IIH, particularly within the UK. Many aspects
are applicable in other countries, as supported
by the subsequent publication of the first
European Headache Federation Guidelines for
IIH [61].
Management of Fulminant IIH
Fulminant IIH is defined as IIH resulting in a
significant reduction in visual function within
4 weeks of diagnosis [1]. Those with fulminant
IIH require emergency surgical management,
aimed at rapidly lowering the CSF pressure [70].
Should surgery be delayed, a lumbar drain can
be inserted to protect vision in the intervening
period [1]. A large systematic review of 109
studies over a 34-year period showed that CSF
diversion procedures for IIH reduced papil-
loedema in 78.9% of cases and prevented visual
field deterioration in 66.8% [71]. The disad-
vantages of shunts are that they are invasive,
carry an infection risk and may require revisions
in up to one-third of patients [72]. Ventriculo-
peritoneal shunts are preferred due to the
reported lower revision rates compared with
lumbo-peritoneal shunts (1.8 versus 4.3 revi-
sions per patient, respectively) [73].
Adjustable valves (antigravity or anti-siphon
devices) can reduce the risk of low-pressure
headaches in the long term [73]. However, it is
important to counsel patients that ventriculo-
peritoneal shunt insertion leads to a temporary
driving restriction in some countries, such as
the UK [1]. Optic nerve sheath fenestration
(ONSF) surgery is another option. Disadvan-
tages of this surgical approach include persis-
tently raised ICP and the severe complication of
risk of vision loss, as well as other complications
such as diplopia [74].
Managing Weight Loss
Weight loss has been shown to be an effective
method for improving headache symptoms,
papilloedema and reducing ICP [30]. Sustaining
weight loss is difficult, with patients on average
regaining one-third to one-half of the weight
that was lost at 1 year and returning to their
original weight within 5 years [75]. For IIH, a
weight gain of 6% has led to documented
recurrences [24].
Bariatric surgery is the most effective method
for sustained weight loss, resulting in 15–30%
weight loss over 15–20 years depending on the
surgical procedure [76]. Gastric bypass (Roux-
en-Y) surgery has been shown to be an effective
method for reducing weight for IIH and can
result in reduction or resolution of papil-
loedema, headache and tinnitus, with a con-
comitant reduction in ICP [29]. In addition,
there is a decrease in circulating leptin, glucose,
insulin and IGF-1, and an increase in adreno-
corticotropic hormone (ACTH), following
bypass surgery [77]. Gastric sleeve surgery has
also been reported to be useful in IIH [78],
leading to sufficient weight loss and resolution
of papilloedema. Bariatric surgery is currently
being investigated in the Idiopathic Intracranial
Hypertension Weight Trial (IIH:WT), an RCT
assessing bariatric surgery against a community
weight-loss programme [79].
Pharmacological Therapy in IIH
Acetazolamide, a carbonic anhydrase inhibitor,
is the main pharmacological therapy for IIH.
Although class I evidence exists for its use in
IIH, only two RCTs to date have examined its
efficacy [10, 31]. In 2014, a large randomised,
double-blind placebo-controlled study of
acetazolamide combined with a low-sodium
diet was published [31]. The IIH treatment trial
(IIHTT) showed that the mean decrease in
perimetric mean deviation (PMD) was statisti-
cally significant for those with mild visual loss
using a low-calorie diet plus acetazolamide,
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compared with a low-calorie diet and placebo,
at 6-months follow-up. In the IIHTT, the bene-
fits were most marked in those with the most
significant papilloedema. High doses of aceta-
zolamide were used, with more than 40% of
patients treated with 4000 mg of acetazolamide
daily. This dose may not be tolerable in a real-
world setting, as previous studies have demon-
strated that 48% of patients discontinue aceta-
zolamide at daily doses of 1500 mg [10]. Side
effects of acetazolamide include paraesthesia,
dysgeusia, vomiting and diarrhoea, as well as
malaise, fatigue and depression [1, 10]. A 2015
Cochrane review [80] highlighted that the
available data are not of sufficient quality, and
therefore the evidence for the use of acetazo-
lamide in IIH is currently limited. Hence, not all
clinicians routinely prescribe acetazolamide for
IIH [1].
Topiramate is a migraine prophylactic with
mild carbonic anhydrase inhibitor activity and
additional appetite suppressant action. Topira-
mate has been reported in an open-label study
comparing its efficacy against acetazolamide
[81]. The dual action of reducing CSF secretion
and reducing migraine is appealing to clini-
cians. A recent in vivo animal study investi-
gated clinical (single equivalent human dose)
and high (daily equivalent human dose) sub-
cutaneous administration of many of the
known drugs used in IIH. Topiramate lowered
ICP in female rats by 21% over peak plasma
drug concentration at 2 h (p = 0.015) and 32%
(p = 0.0009), respectively. Of note, there was no
significant reduction in ICP noted with human
equivalent doses of acetazolamide 4000 g,
amiloride 20 mg, octreotide 2 mg or furosemide
240 mg. The report also examined oral admin-
istration of topiramate and found that it sig-
nificantly lowered ICP by 22% (p = 0.018),
compared to a 5% reduction with acetazo-
lamide (p =[0.999) [82]. Human physiological
studies would be further informative in assess-
ing ICP levels in response to common medica-
tions used. Topiramate has also been used
successfully to treat headache in IIH. Common
side effects include reduced appetite, paraes-
thesia, and cognitive and concentration
impairment. Caution is advised for those with
prior history of depression, and due to its
teratogenicity, appropriate contraception is
recommended in women who are of reproduc-
tive age [1, 61].
11b-hydroxysteroid dehydrogenase type 1
(11b-HSD1) blocking agents have recently been
identified as potentially beneficial in IIH. The
choroid plexus expresses 11b-HSD1 to amplify
cortisol availability and also aids in the regula-
tion of CSF production [43]. The IIH Drug Trial
was a recent RCT comparing the selective 11b-
HSD1 inhibitor AZD4017 versus placebo.
Thirty-one patients were randomised to either
the intervention (n = 17) or control (n = 14).
This trial highlighted that AZD4017 was safe,
well tolerated and showed trends towards ICP
reduction [83]. An exploratory analysis assess-
ing mean change in LP pressure within each
group found a significant decrease in the
AZD4017 group [mean change: -4.3 cmH2O
(SD = 5.7); P = 0.009] but not in the placebo
group [mean change: -0.3 cmH2O
(SD = 5.9); P = 0.8] [83]. The authors therefore
highlight that this drug may be useful in treat-
ing IIH, with improved tolerability compared to
the currently used medications.
Other Interventions for IIH
Anecdotally, patients have reported that diag-
nostic lumbar puncture (LP) improves headache
in IIH. A cohort study demonstrated that LP
does indeed improve headache symptoms, but
only to a mild degree, and with variable success
across studies [84]. Post-LP exacerbation head-
ache is common, particularly in patients
reporting mild headache on the day of the
procedure, where 81% reported such an exac-
erbation [84]. Furthermore, 40% of patients
report ’severe pain’ and 47% of patients report
‘extreme anxiety’ associated with the procedure
[85]. Therefore, consensus guidelines do not
support the use of serial LP without discerning
evidence [86]. The increasing use of telemetric
ICP monitors will provide valuable insights into
CSF dynamics and the effects of therapeutic LP
in the future [12]. Dural venous sinus stenting
(VSS) is an evolving area of research for those
identified with a focal venous sinus stenosis, as
discussed in the pathogenesis above [87–89]. A
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recent meta-analysis of 474 patients confirmed
papilloedema resolution in 94% and improved
headache outcomes in 77% of cases [90]. The
most common side effect in up to half of those
treated is transient headache of less than 7 days,
usually ipsilateral to the stent [91]. Rarer, but
serious, side effects that have been reported
include intracranial haemorrhage, venous sinus
thrombosis, femoral pseudoaneurysm, transient
hearing loss, allergic reaction to contrast,
retroperitoneal hematoma, neck hematoma,
stent migration and death. In the meta-analysis,
complications occurred in 2% of patients, while
recurrence of IIH symptoms following VSS
occurred in 10% of cases [90]. All advocate
anticoagulation, with the majority being hep-
arinised prior to the procedure, with subsequent
maintenance therapy for a period of 6 months
up to life. Overall, the results which have been
published thus far are encouraging, although
they are drawn from observational case series
and are thus susceptible to a number of biases. A
recent review by Gurney et al. highlighted the
need for robust RCTs to investigate venous
sinus stenting in the management of IIH [92].
PATIENT MONITORING
AND PROGNOSIS
The course of disease in IIH is variable. Visual
monitoring is essential for patients with active
disease, and where there is deteriorating visual
function, a step in management may be
required. Imaging the fundus (e.g. colour fun-
dus photography) is useful for longitudinal
assessment. Optical coherence tomography
(OCT) is increasingly being utilised to objec-
tively monitor changes in the retinal nerve fibre
layer (RNFL) and the optic nerve head disc
(ONH) volume to track papilloedema. For
example, Figs. 1 and 2 show the improvement
in the RNFL and ONH volume, respectively, in a
29-year-old female Caucasian who was diag-
nosed with IIH. Through lifestyle and beha-
vioural modification alone, she lost 17 kg over
6 months. Her BMI reduced from 35.6 to
28.8 kg/m2. OCT RNFL must be interpreted
cautiously, as a reduction in elevation of the
RNFL may indicate resolving papilloedema and/
or loss of retinal nerve fibres leading to optic
atrophy. Therefore, the use of macular ganglion
cell analysis may be more helpful in IIH
[93].When imaging papilloedema, the scans can
Fig. 1 Optical coherence tomography (OCT) images
showing change in disc swelling over the time period.
a Infrared image of the right optic nerve at presentation;
b infrared image of the right optic nerve following weight
loss; c the central cross section and the amount of
reduction in the retinal nerve fibre layer in the right eye.
d Infrared image of the left optic nerve at presentation;
e infrared image of the left optic nerve following weight
loss; f the central cross section and the amount of
reduction in the retinal nerve fibre layer in the left eye
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be prone to proprietary software segmentation
error; therefore a qualitative assessment of the
traces within the OCT should be made and
adjustments in the segmentation made to
ensure the reliability of the OCT parameters for
longitudinal follow-up [94].
The severity of papilloedema, as graded using
the modified Frisén scale, has been shown to be
a predictor of final visual outcome, rather than
cotton wool spots or retinal hemorrhages as
previously thought [95]. Racial disparities may
exist, with poorer visual outcomes in those of
African ancestry compared with White Ameri-
cans [96]. Other studies have examined the
anatomical changes in the optic canal to predict
visual outcome, but these have shown con-
flicting results. An MRI study [97] reported poor
visual function and severe papilloedema or
optic atrophy in association with a larger optic
canal, while a CT imaging study [98] found no
correlation between any of the optic canal
measurements and papilloedema grade and no
significant difference in optic canal measure-
ments between IIH patients and controls.
Fig. 2 The disc volume segments and change in volume over the time period. Top image—latest, middle image—at
presentation, bottom image—change in volume. a Right eye. b Left eye
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For the majority, IIH is a chronic condition
with disabling headaches that necessitates
active management [56]. Migraine headaches
are common in IIH patients [99, 100]. Headache
has been shown to be one of the most impor-
tant determinants of quality of life in individ-
uals with IIH [7]. There appears to be a lack of
correlation between headache frequency and
severity, and recorded LP opening pressure
[100], and the latest guidelines for the classifi-
cation of headache attributable to IIH have
removed reference to improvement of headache
with reduction of ICP [58]. The IIH consensus
guidelines recommend a stepwise approach for
pharmacological treatment of headache [1].
Medication overuse headache is common in IIH
and should be eliminated to optimise subse-
quent therapy [8]. Once the ICP has been
reduced, migraine abortive medications may be
more effective. Preventive migraine pharma-
cotherapy can then follow. It is important to
avoid medications that have side effects which
result in weight gain, due to the strong corre-
lation between weight gain and IIH sympto-
mology [1, 61]. Drugs that can potentially alter
mood should generally be avoided [1, 61].
CONCLUSIONS
IIH is a challenging disease which crosses many
medical disciplines. Guidelines are helping
clinicians to benchmark their management
protocols. With increasing incidence of IIH,
there is no better time to explore the underlying
pathophysiology to help inform discovery of
novel therapeutic agents to improve treatment
of this disabling disease.
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